Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

Everolimus, an mTOR inhibitor, which has been demonstrated to induce anti-tumour effects in different types of neuroendocrine tumours, has never been evaluated in patients with medullary thyroid cancer (MTC). The aim of this study was to evaluate the in vitro and in vivo effects of everolimus in com...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Faggiano, A, Ramundo, V, Dicitore, A, Castiglioni, S, Borghi, M O, Severino, R, Ferolla, P, Crinò, L, Abbruzzese, A, Sperlongano, P, Caraglia, M, Ferone, D, Hofland, L, Colao, A, Vitale, G
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2012
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3823224/
https://ncbi.nlm.nih.gov/pubmed/21883896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1582-4934.2011.01438.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars